2007-001630-14: Safety and efficacy of efalizumab in combination with methotrexate in patients with severe psoriasis: a comparative study. |
|
|
| Ongoing | 4 | 30 | Europe | Raptiva, Raptiva | University Medical Centre St. Radboud, Department of Dermatology | Moderate to severe chronic plaque psoriasis | | | | |
2007-001377-28: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) |
|
|
| | 4 | 10 | Europe | Raptiva 100 mg/ml powder and solvent for solution for injection, Raptiva 100 mg/ml powder and solvent for solution for injection | Merck Serono International S.A. | Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia. | | 07/09 | | |
